Global Molecular Epidemiology of Respiratory Syncytial Virus from the 2017-2018 INFORM-RSV Study

David E Tabor1, Fiona Fernandes2, Annefleur C Langedijk3

  • 1Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.

Insights

Global molecular epidemiology of Respiratory Syncytial Virus (RSV) was studied in children under 5. The pilot season found RSV B predominated globally, with genetic variations impacting potential vaccine and MAb effectiveness.

Area of Science:

  • Virology
  • Epidemiology
  • Molecular Biology

Background:

  • Respiratory Syncytial Virus (RSV) causes significant lower respiratory tract infections in young children globally.
  • Annual epidemics of RSV necessitate continuous monitoring of circulating strains and their evolution.

Purpose of the Study:

  • To describe the global molecular epidemiology of RSV in children under 5.
  • To monitor temporal and geographical evolution of RSV strains, F protein antigenic sites, and their relation to clinical features.
  • To establish a baseline for tracking new strains and potential immune escape variants.

Main Methods:

  • The INFORM-RSV pilot season (2017-2018) collected 476 RSV-positive nasal samples from 8 countries.
  • 410 RSV G-F gene sequences were analyzed to determine strain distribution and genetic variability.
  • Sequences were compared to 2013 reference strains to identify variations in F protein antigenic sites.

Main Results:

  • RSV B (BA9 genotype) predominated globally (69.0%) over RSV A (ON1 genotype) (31.0%), except in South Africa.
  • Geographic clustering indicated widespread transmission and ongoing viral evolution.
  • Variations in F protein antigenic sites were observed, particularly in RSV B strains at sites Ø and V.

Conclusions:

  • The 2017-2018 pilot season provides a crucial molecular baseline for RSV epidemiology.
  • Ongoing monitoring is essential to track emerging strains and potential neutralization escape variants.
  • Findings will inform the development and effectiveness assessment of RSV vaccines and monoclonal antibodies.

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.9K
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
38.5K
Principles of Disease Surveillance01:26

Principles of Disease Surveillance

Disease surveillance is the systematic collection, analysis, and interpretation of health data essential to the planning, implementation, and evaluation of public health practice. This process integrates data dissemination to entities responsible for preventing and controlling disease, injury, and disability. Surveillance systems provide crucial information for action, helping public health authorities make informed decisions to manage and prevent outbreaks, ensure public safety, optimize...
364